Lookup NU author(s): Dr Sophie West,
Dr Ben Prudon,
This is the authors' accepted manuscript of an article that has been published in its final definitive form by European Respiratory Society, 2018.
For re-use rights please refer to the publisher's terms and conditions.
Objective: We sought to establish whether CPAP for OSA in people with type 2 diabetes and diabetic macular oedema (DME) improved visual acuity.Methods: We randomly assigned 131 eligible patients aged 30–85 years from 23 UK centres with significant DME causing visual impairment (LogMAR letters identified, = 39–= 78, score 0.92–0.14) plus severe OSA on screening to either: usual ophthalmology care (n=67) or usual ophthalmology care plus CPAP (n=64) for 12 months.Results: Mean age of participants was 64 years, 73% male, mean BMI 35.0 kg·m-2. Mean 4% oxygen desaturation index was 36/hour. There was no significant difference in the visual acuity at twelve months between the CPAP group and the control group, mean LogMAR (95%CI) 0.33 (0.29, 0.37) versus 0.31 (0.27, 0.35), p=0.39, and no significant correlation between change in LogMAR and average CPAP use. The median daily CPAP use (sd, range) was 3.33 (2.25, 0–7.93) hours at three months, 3.19 (2.54, 0–8.07) hours at six months and 3.21 (2.7, 0–7.98) hours at twelve months.Conclusion: CPAP therapy for OSA did not improve visual acuity in people with type 2 iabetes and diabetic macular oedema compared to usual care alone over 12 months.
Author(s): West SD, Prudon B, Hughes J, Gupta R, Mohammed SB, Gerry S, Stradling JR
Publication type: Article
Publication status: Published
Journal: European Respiratory Journal
Print publication date: 01/10/2018
Online publication date: 30/08/2018
Acceptance date: 30/08/2018
Date deposited: 12/09/2018
ISSN (print): 0903-1936
ISSN (electronic): 1399-3003
Publisher: European Respiratory Society
PubMed id: 30166323
Altmetrics provided by Altmetric